Conexeu Sciences Sees a New Category Forming in Medical Aesthetics as Research Turns to Regeneration
RENO, Nev., Aug.
18, 2026 (GLOBE NEWSWIRE) -- Conexeu Sciences Inc. (Nasdaq: CNXU) (“Conexeu” or the “Company”), a preclinical-stage biotechnology company advancing an investigational tissue-restoration platform, believes a new category is emerging within medical aesthetics centered on regenerative tissue restoration.
Rather than focusing solely on replacing lost volume, this developing area of medicine is increasingly exploring approaches aimed at restoring, rebuilding, enhancing, and contouring soft tissue.
Conexeu believes the opportunity spans facial rejuvenation, age-related tissue changes, post-weight-loss restoration, soft-tissue enhancement, and body contouring, areas where patients increasingly seek natural-looking outcomes supported by biological restoration.
Read More
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on financialpost.com — the content belongs to Financial Post.